Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Pubmed

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

The Lancet , Volume 390 (10105): 10 – Sep 27, 2018

Loading next page...
 
/lp/pubmed/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-0TidGx4P12

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0140-6736
DOI
10.1016/S0140-6736(17)31601-X
pmid
28822576

Abstract

Journal

The LancetPubmed

Published: Sep 27, 2018

There are no references for this article.